Literature DB >> 10451695

The anti-inflammatory effects of macrolides.

D Wales1, M Woodhead.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10451695      PMCID： PMC1765933          DOI： 10.1136/thx.54.2008.s58

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  32 in total

1.  Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils.

Authors:  M T Labro; J el Benna; C Babin-Chevaye
Journal:  J Antimicrob Chemother       Date:  1989-10       Impact factor: 5.790

2.  Partial lobectomy of bovine liver: a new biopsy technique.

Authors:  D A Witzel; J H Johnson; R L Younger
Journal:  Cornell Vet       Date:  1975-01

3.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

4.  Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung.

Authors:  S Nelson; W R Summer; P B Terry; G A Warr; G J Jakab
Journal:  Am Rev Respir Dis       Date:  1987-11

5.  Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes.

Authors:  W L Hand; D L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  [Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis].

Authors:  M Yamamoto; A Kondo; M Tamura; T Izumi; Y Ina; M Noda
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1990-10

7.  Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation.

Authors:  R Anderson
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

8.  A pilot study of low-dose erythromycin in bronchiectasis.

Authors:  K W Tsang; P I Ho; K N Chan; M S Ip; W K Lam; C S Ho; K Y Yuen; G C Ooi; R Amitani; E Tanaka
Journal:  Eur Respir J       Date:  1999-02       Impact factor: 16.671

9.  Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells.

Authors:  H Takizawa; M Desaki; T Ohtoshi; S Kawasaki; T Kohyama; M Sato; J Nakajima; M Yanagisawa; K Ito
Journal:  Eur Respir J       Date:  1998-07       Impact factor: 16.671

10.  Studies on the effects of ingestion of a single 500 mg oral dose of erythromycin stearate on leucocyte motility and transformation and on release in vitro of prostaglandin E2 by stimulated leucocytes.

Authors:  R Anderson; A C Fernandes; H E Eftychis
Journal:  J Antimicrob Chemother       Date:  1984-07       Impact factor: 5.790
View more
  20 in total

1.  Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis.

Authors:  Paul Beringer; Kitty My Tu Huynh; Jane Kriengkauykiat; Luke Bi; Nils Hoem; Stan Louie; Emily Han; Thao Nguyen; Donald Hsu; Purush A Rao; Bertrand Shapiro; Mark Gill
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.

Authors:  Tomoki Maekawa; Hikaru Tamura; Hisanori Domon; Takumi Hiyoshi; Toshihito Isono; Daisuke Yonezawa; Naoki Hayashi; Naoki Takahashi; Koichi Tabeta; Takeyasu Maeda; Masataka Oda; Athanasios Ziogas; Vasileia Ismini Alexaki; Triantafyllos Chavakis; Yutaka Terao; George Hajishengallis
Journal:  JCI Insight       Date:  2020-08-06

Review 3.  Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin.

Authors:  André G Buret
Journal:  Can J Vet Res       Date:  2010-01       Impact factor: 1.310

Review 4.  Asthma in children: are chlamydia or mycoplasma involved?

Authors:  S Esposito; N Principi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

6.  Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression.

Authors:  María-Jesús Sanz; Yafa Naim Abu Nabah; Miguel Cerdá-Nicolás; José-Enrique O'Connor; Andrew C Issekutz; Julio Cortijo; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

7.  Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone.

Authors:  E García Vázquez; J Mensa; J A Martínez; M A Marcos; J Puig; M Ortega; A Torres
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

8.  Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.

Authors:  Freddy Frost; Matthew Shaw; Dilip Nazareth
Journal:  Cochrane Database Syst Rev       Date:  2019-06-13

Review 9.  Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy.

Authors:  Duncan F Rogers
Journal:  Curr Allergy Asthma Rep       Date:  2003-05       Impact factor: 4.919

10.  Chronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches.

Authors:  Harsha H Kariyawasam; Glenis K Scadding
Journal:  Allergy Asthma Immunol Res       Date:  2011-09-01       Impact factor: 5.764
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.